SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study

Rhea-AI Summary

SomaLogic (NASDAQ: SLGC) announced its collaboration with the Multi-Ethnic Study of Atherosclerosis (MESA), beginning in Q1 2022. The company will analyze 105 million protein measurements from 15,000 samples collected over 15 years, focusing on subclinical cardiovascular disease. The data will be accessible to researchers, enhancing understanding of various diseases, including COVID-19 and diabetes. The partnership underlines SomaLogic's commitment to data-sharing, aiming to advance healthcare solutions and improve human health outcomes. This represents a significant milestone in proteomic research.

Positive

• Collaboration with MESA to analyze 105 million protein measurements.
• Enhancement of understanding various diseases through shared data.
• Significant dataset expected to expedite research and improve health outcomes.

Negative

• None.

Data will be available to researchers studying a wide range of disease states

BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis (MESA) study beginning in the first quarter of 2022. SomaLogic will use its industry-leading assay to analyze 105 million protein measurements from 15,000 samples spanning 15 years of clinical interactions. The MESA study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Under the guidelines set by the NHLBI, the data from the SomaScan^® assay will be made available for analysis by researchers from the MESA program and the broader scientific community.

“The MESA study is groundbreaking and we expect it to generate the largest proteomic dataset of an ethnically diverse population,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “This agreement represents yet another demonstration of SomaLogic’s support of the data-sharing and data-access policies of the National Institutes of Health that nurture the research enterprise. We hope that sharing this data will expedite its translation into knowledge, products and procedures that make a positive impact on human health.”

The MESA study is focused on subclinical cardiovascular disease and the risk factors that predict progression to clinical signs and symptoms. The study includes a diverse group of 6,814 asymptomatic men and women, ranging in age from 45 to 84 when the study began in 1999. According to the MESA website, approximately 38% of the participants in the study are white, 28% are African-American, 22% are Hispanic and 12% are Asian. Participants are seen in six clinics: Columbia University, Johns Hopkins University, Northwestern University, UCLA, University of Minnesota and Wake Forest University. Because the data is shared with outside investigators, this study has also been used by hundreds of investigators to understand other diseases, including COVID-19, eye disease and non-alcoholic steatohepatitis (NASH).

SomaLogic will use the SomaScan assay data from the MESA study, as well as information from clinical visits and health histories, to further validate its SomaSignal™ tests, specifically for cardiovascular disease, diabetes risk and NASH.

“MESA is widely regarded an unique landmark study because of multiple sequential clinical evaluations and blood samples over many years in a multi-ethnic cohort,” said SomaLogic Chief Medical Officer Stephen A. Williams. “As the basis for new discoveries from studying 7,000 proteins in each person’s samples - the largest fraction of the proteome ever studied at scale – this collaboration is an unprecedented opportunity to evaluate the downstream proteomic impact of genetic and environmental factors on human health and aging.”

About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory. 

SomaLogic Contact        
Emilia Costales                
720-798-5054
ecostales@somalogic.com

Investor Contact
Lynn Lewis or Marissa Bych
Gilmartin Group LLC
investors@somalogic.com

FAQ

What is SomaLogic's recent partnership related to?

SomaLogic has partnered with the Multi-Ethnic Study of Atherosclerosis (MESA) to analyze protein measurements, enhancing research on cardiovascular diseases.

What will SomaLogic analyze from the MESA study?

SomaLogic will analyze 105 million protein measurements from 15,000 samples gathered over 15 years.

When will SomaLogic start working with the MESA data?

SomaLogic will begin analyzing MESA data in the first quarter of 2022.

Why is the MESA study significant for SomaLogic?

The MESA study provides a unique, ethnically diverse dataset that will help validate SomaLogic's SomaSignal tests for various health conditions.

What diseases may benefit from the SomaLogic and MESA study collaboration?

The collaboration aims to enhance understanding of cardiovascular disease, diabetes risk, and non-alcoholic steatohepatitis (NASH).